Xeris Biopharma (XERS) Competitors

$6.38 -0.05 (-0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$6.38 0.00 (-0.08%)

As of 05:41 PM Eastern

XERS vs. KNSA, NAMS, AMRX, MANE, and TVTX

Should you buy Xeris Biopharma stock or one of its competitors? MarketBeat compares Xeris Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xeris Biopharma include Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Amneal Pharmaceuticals (AMRX), MANE (MANE), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry.

How does Xeris Biopharma compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Xeris Biopharma. Kiniksa Pharmaceuticals International is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	6.65	$59.01M	$0.90	65.04
Xeris Biopharma	$314.85M	3.50	$550K	$0.06	106.33

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 6.5% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Xeris Biopharma's net margin of 3.81%. Xeris Biopharma's return on equity of 735.00% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Xeris Biopharma	3.81%	735.00%	3.24%

Kiniksa Pharmaceuticals International presently has a consensus price target of $60.86, indicating a potential upside of 3.96%. Xeris Biopharma has a consensus price target of $10.80, indicating a potential upside of 69.28%. Given Xeris Biopharma's higher possible upside, analysts plainly believe Xeris Biopharma is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Kiniksa Pharmaceuticals International has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

In the previous week, Xeris Biopharma had 11 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 14 mentions for Xeris Biopharma and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat Xeris Biopharma's score of 0.58 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats Xeris Biopharma on 11 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to NewAmsterdam Pharma?

Xeris Biopharma (NASDAQ:XERS) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Xeris Biopharma has a net margin of 3.81% compared to NewAmsterdam Pharma's net margin of -943.23%. Xeris Biopharma's return on equity of 735.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Xeris Biopharma currently has a consensus price target of $10.80, suggesting a potential upside of 69.28%. NewAmsterdam Pharma has a consensus price target of $48.00, suggesting a potential upside of 30.15%. Given Xeris Biopharma's higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 6.5% of Xeris Biopharma shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Xeris Biopharma has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$314.85M	3.50	$550K	$0.06	106.33
NewAmsterdam Pharma	$22.50M	188.45	-$203.82M	-$1.79	N/A

In the previous week, NewAmsterdam Pharma had 6 more articles in the media than Xeris Biopharma. MarketBeat recorded 20 mentions for NewAmsterdam Pharma and 14 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.58 beat NewAmsterdam Pharma's score of 0.58 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	5 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Xeris Biopharma has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market.

Summary

Xeris Biopharma beats NewAmsterdam Pharma on 10 of the 17 factors compared between the two stocks.

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Xeris Biopharma (NASDAQ:XERS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Xeris Biopharma's net margin of 3.81%. Xeris Biopharma's return on equity of 735.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

Xeris Biopharma currently has a consensus price target of $10.80, suggesting a potential upside of 69.28%. Amneal Pharmaceuticals has a consensus price target of $15.00, suggesting a potential upside of 22.65%. Given Xeris Biopharma's higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Xeris Biopharma had 10 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Xeris Biopharma and 4 mentions for Amneal Pharmaceuticals. Xeris Biopharma's average media sentiment score of 0.58 beat Amneal Pharmaceuticals' score of 0.42 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals has higher revenue and earnings than Xeris Biopharma. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$314.85M	3.50	$550K	$0.06	106.33
Amneal Pharmaceuticals	$3.05B	1.26	$72.06M	$0.38	32.18

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 6.5% of Xeris Biopharma shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Xeris Biopharma has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Xeris Biopharma on 9 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to MANE?

Xeris Biopharma (NASDAQ:XERS) and MANE (NYSE:MANE) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Xeris Biopharma has a net margin of 3.81% compared to MANE's net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat MANE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
MANE	N/A	N/A	N/A

Xeris Biopharma currently has a consensus price target of $10.80, suggesting a potential upside of 69.28%. MANE has a consensus price target of $83.33, suggesting a potential downside of 21.27%. Given Xeris Biopharma's higher probable upside, equities research analysts plainly believe Xeris Biopharma is more favorable than MANE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Xeris Biopharma had 10 more articles in the media than MANE. MarketBeat recorded 14 mentions for Xeris Biopharma and 4 mentions for MANE. Xeris Biopharma's average media sentiment score of 0.58 beat MANE's score of 0.17 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MANE	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Xeris Biopharma has higher revenue and earnings than MANE.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$314.85M	3.50	$550K	$0.06	106.33
MANE	N/A	N/A	N/A	N/A	N/A

42.8% of Xeris Biopharma shares are held by institutional investors. 6.5% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Xeris Biopharma beats MANE on 9 of the 10 factors compared between the two stocks.

How does Xeris Biopharma compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

42.8% of Xeris Biopharma shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by company insiders. Comparatively, 6.5% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Xeris Biopharma has a net margin of 3.81% compared to Travere Therapeutics' net margin of -4.00%. Xeris Biopharma's return on equity of 735.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Xeris Biopharma	3.81%	735.00%	3.24%

Xeris Biopharma has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	8.36	-$25.55M	-$0.23	N/A
Xeris Biopharma	$314.85M	3.50	$550K	$0.06	106.33

In the previous week, Travere Therapeutics had 2 more articles in the media than Xeris Biopharma. MarketBeat recorded 16 mentions for Travere Therapeutics and 14 mentions for Xeris Biopharma. Travere Therapeutics' average media sentiment score of 0.76 beat Xeris Biopharma's score of 0.58 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	6 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics presently has a consensus price target of $47.83, suggesting a potential upside of 8.47%. Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 69.28%. Given Xeris Biopharma's higher possible upside, analysts plainly believe Xeris Biopharma is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Travere Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Summary

Xeris Biopharma beats Travere Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Xeris Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XERS vs. The Competition

Export

Metric	Xeris Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.10B	$3.04B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	106.33	19.11	20.87	25.58
Price / Sales	3.50	278.37	521.63	63.56
Price / Cash	62.50	56.53	42.94	55.34
Price / Book	79.75	4.35	9.86	6.70
Net Income	$550K	$72.19M	$3.55B	$333.77M
7 Day Performance	-3.77%	-0.60%	-0.32%	0.45%
1 Month Performance	5.11%	0.25%	1.34%	4.06%
1 Year Performance	37.50%	46.24%	41.03%	36.21%

Xeris Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XERS Xeris Biopharma	3.0163 of 5 stars	$6.38 -0.8%	$10.80 +69.3%	+31.2%	$1.10B	$314.85M	106.33	290	Earnings Report Analyst Downgrade Analyst Revision
KNSA Kiniksa Pharmaceuticals International	3.4327 of 5 stars	$58.37 -0.4%	$60.86 +4.3%	+130.9%	$4.51B	$677.56M	64.86	220	Positive News
NAMS NewAmsterdam Pharma	3.4131 of 5 stars	$39.59 +2.2%	$48.00 +21.2%	+101.3%	$4.45B	$22.50M	N/A	4	Earnings Report Analyst Revision Gap Down High Trading Volume
AMRX Amneal Pharmaceuticals	4.1315 of 5 stars	$12.78 -3.2%	$15.00 +17.4%	+65.2%	$4.15B	$3.02B	33.63	8,500	Earnings Report Analyst Upgrade Insider Trade
MANE MANE	N/A	$108.84 +2.5%	$83.33 -23.4%	N/A	$3.96B	N/A	N/A	19	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XERS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xeris Biopharma (XERS) Competitors

XERS vs. KNSA, NAMS, AMRX, MANE, and TVTX

How does Xeris Biopharma compare to Kiniksa Pharmaceuticals International?

Summary

How does Xeris Biopharma compare to NewAmsterdam Pharma?

Summary

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Summary

How does Xeris Biopharma compare to MANE?

Summary

How does Xeris Biopharma compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xeris Biopharma (XERS) Competitors

XERS vs. KNSA, NAMS, AMRX, MANE, and TVTX

How does Xeris Biopharma compare to Kiniksa Pharmaceuticals International?

Which has better earnings and valuation, KNSA or XERS?

Do insiders & institutionals believe in KNSA or XERS?

Is KNSA or XERS more profitable?

Do analysts recommend KNSA or XERS?

Which has more risk & volatility, KNSA or XERS?

Does the media refer more to KNSA or XERS?

Summary

How does Xeris Biopharma compare to NewAmsterdam Pharma?

Is XERS or NAMS more profitable?

Do analysts rate XERS or NAMS?

Do institutionals & insiders have more ownership in XERS or NAMS?

Which has better earnings and valuation, XERS or NAMS?

Does the media favor XERS or NAMS?

Which has more volatility & risk, XERS or NAMS?

Summary

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Is XERS or AMRX more profitable?

Do analysts rate XERS or AMRX?

Does the media favor XERS or AMRX?

Which has better earnings and valuation, XERS or AMRX?

Do institutionals & insiders have more ownership in XERS or AMRX?

Which has more volatility & risk, XERS or AMRX?

Summary

How does Xeris Biopharma compare to MANE?

Is XERS or MANE more profitable?

Do analysts rate XERS or MANE?

Does the media refer more to XERS or MANE?

Which has preferable valuation & earnings, XERS or MANE?

Do insiders and institutionals have more ownership in XERS or MANE?

Summary

How does Xeris Biopharma compare to Travere Therapeutics?

Do institutionals and insiders have more ownership in TVTX or XERS?

Is TVTX or XERS more profitable?

Which has higher valuation & earnings, TVTX or XERS?

Does the media refer more to TVTX or XERS?

Do analysts prefer TVTX or XERS?

Which has more risk & volatility, TVTX or XERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools